Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?

Kwonjune Seung and colleagues describe the Eugene Bell Foundation's experience of treating MDR-TB in North Korea.

Vyšlo v časopise: Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?. PLoS Med 13(8): e32767. doi:10.1371/journal.pmed.1002062
Kategorie: Health in Action
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002062

Souhrn

Kwonjune Seung and colleagues describe the Eugene Bell Foundation's experience of treating MDR-TB in North Korea.

Zdroje

1. World Health Organization. Global tuberculosis control 2015 (WHO/HTM/TB/2014.22). Geneva: World Health Organization; 2015.

2. Seung KJ, Linton SW. The growing problem of multidrug-resistant tuberculosis in North Korea. PLoS Med. 2013; 10(7): e1001486. doi: 10.1371/journal.pmed.1001486 23935457

3. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8): e1001300. 22952439

4. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004; 363(9407): 474–81. 14962530

5. The Global Fund. Korea (Democratic Peoples Republic). [cited 21 Nov 2015]. http://www.theglobalfund.org/en/portfolio/country/?loc=PRK

6. World Health Organization. Management of MDR-TB: A field guide (WHO/HTM/TB/2008.402). Geneva: World Health Organization; 2009.

7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update (WHO/HTM/TB/2011.6). Geneva: World Health Organization; 2011.

8. Pardini M, Varaine F, Iona E, Arzumanian E, Checchi F, Oggioni MR, et al. Cetyl-pyridinium chloride is useful for isolation of Mycobacterium tuberculosis from sputa subjected to long-term storage. J Clin Micro. 2005; 43(1): 442–444.

9. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182: 113–119. doi: 10.1164/rccm.200911-1656OC 20224066

10. Jeon DS, Shin DO, Park SK, Seo JE, Seo HS, Cho YS, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci. 2011; 26: 33–41. doi: 10.3346/jkms.2011.26.1.33 21218027

11. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012; 17(3): 299–307. doi: 10.5588/ijtld.12.0537 23211716

12. Farmer P. Managerial successes, clinical failures. Int J Tuberc Lung Dis. 1999; 3(5): 365–7.

13. The Global Fund. Concept Note (2015 –Tuberculosis) [cited 21 Nov 2015]. http://www.theglobalfund.org/ProgramDocuments/PRK/ConceptNotes/2015/PRK-T_ConceptNote_0_en/

14. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Geneva: World Health Organization; 2014.

15. Foundation for Innovative New Diagnostics. Price for Xpert® MTB/RIF and FIND country list [cited 2015 Aug 7]. http://www.finddx.org/pricing/